| Product Code: ETC7341054 | Publication Date: Sep 2024 | Updated Date: Sep 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Ghana mRNA Vaccines and RNAi Therapeutics Market Overview |
3.1 Ghana Country Macro Economic Indicators |
3.2 Ghana mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, 2021 & 2031F |
3.3 Ghana mRNA Vaccines and RNAi Therapeutics Market - Industry Life Cycle |
3.4 Ghana mRNA Vaccines and RNAi Therapeutics Market - Porter's Five Forces |
3.5 Ghana mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume Share, By Disease Type, 2021 & 2031F |
3.6 Ghana mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume Share, By Administration, 2021 & 2031F |
3.7 Ghana mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume Share, By End user, 2021 & 2031F |
4 Ghana mRNA Vaccines and RNAi Therapeutics Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing government initiatives and funding for healthcare infrastructure and research in Ghana |
4.2.2 Growing awareness about mRNA vaccines and RNAi therapeutics for various diseases in the country |
4.2.3 Rise in collaborations and partnerships between local and international pharmaceutical companies in the Ghanaian market |
4.3 Market Restraints |
4.3.1 Limited access to advanced healthcare facilities and technologies in certain regions of Ghana |
4.3.2 High costs associated with mRNA vaccines and RNAi therapeutics, limiting affordability for a significant portion of the population |
5 Ghana mRNA Vaccines and RNAi Therapeutics Market Trends |
6 Ghana mRNA Vaccines and RNAi Therapeutics Market, By Types |
6.1 Ghana mRNA Vaccines and RNAi Therapeutics Market, By Disease Type |
6.1.1 Overview and Analysis |
6.1.2 Ghana mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Disease Type, 2021- 2031F |
6.1.3 Ghana mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Hereditary transthyretin-mediated amyloidosis genetic, 2021- 2031F |
6.1.4 Ghana mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Acute hepatic porphyria, 2021- 2031F |
6.1.5 Ghana mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Primary hyperoxaluria type 1, 2021- 2031F |
6.1.6 Ghana mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Atherosclerotic cardiovascular disease, 2021- 2031F |
6.2 Ghana mRNA Vaccines and RNAi Therapeutics Market, By Administration |
6.2.1 Overview and Analysis |
6.2.2 Ghana mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By IV infusion, 2021- 2031F |
6.2.3 Ghana mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Subcutaneous, 2021- 2031F |
6.3 Ghana mRNA Vaccines and RNAi Therapeutics Market, By End user |
6.3.1 Overview and Analysis |
6.3.2 Ghana mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Research Institutes, 2021- 2031F |
6.3.3 Ghana mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Hospitals and Clinics, 2021- 2031F |
7 Ghana mRNA Vaccines and RNAi Therapeutics Market Import-Export Trade Statistics |
7.1 Ghana mRNA Vaccines and RNAi Therapeutics Market Export to Major Countries |
7.2 Ghana mRNA Vaccines and RNAi Therapeutics Market Imports from Major Countries |
8 Ghana mRNA Vaccines and RNAi Therapeutics Market Key Performance Indicators |
8.1 Number of clinical trials conducted for mRNA vaccines and RNAi therapeutics in Ghana |
8.2 Adoption rate of mRNA vaccines and RNAi therapeutics by healthcare providers in the country |
8.3 Percentage increase in research and development investments by pharmaceutical companies in Ghana |
9 Ghana mRNA Vaccines and RNAi Therapeutics Market - Opportunity Assessment |
9.1 Ghana mRNA Vaccines and RNAi Therapeutics Market Opportunity Assessment, By Disease Type, 2021 & 2031F |
9.2 Ghana mRNA Vaccines and RNAi Therapeutics Market Opportunity Assessment, By Administration, 2021 & 2031F |
9.3 Ghana mRNA Vaccines and RNAi Therapeutics Market Opportunity Assessment, By End user, 2021 & 2031F |
10 Ghana mRNA Vaccines and RNAi Therapeutics Market - Competitive Landscape |
10.1 Ghana mRNA Vaccines and RNAi Therapeutics Market Revenue Share, By Companies, 2024 |
10.2 Ghana mRNA Vaccines and RNAi Therapeutics Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here